Back to company

Resistance Oncology ApS: Financial statements 2023

CVR: 36945125

Resistance Oncology ApS (CVR 36945125) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -21,005 and a net result of DKK -22,028 compared with DKK -10,252 the year before. Equity amounted to DKK -63,459. The company had 1 employee in the financial year.

Gross Profit
-21,005 kr.
Profit/Loss
-22,028 kr.
Equity
-63,459 kr.
Total Assets
49,163 kr.
Employees
1

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2023--21 t.-22 t.-63 t.1
2022--12 t.-10 t.-41 t.-
2021--10 t.-9 t.-31 t.-
2020--10 t.-8 t.-23 t.-
2019-14 t.10 t.-15 t.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2023

Cortris Nordic ApS changes name to 3B-Oncology ApSAug 25, 2023

On August 25, 2023, the company changed its name from Cortris Nordic ApS to 3B-Oncology ApS.

Resistance Oncology ApS: The 2022 annual report is outJul 6, 2023

Resistance Oncology ApS has published its annual report for 2022. Gross profit came to DKK -11,970, and the net result was DKK -10,252.

About Resistance Oncology ApS

Resistance Oncology ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named 3B-Oncology ApS and Cortris Nordic ApS. The management consists of Nils Aage Brünner and Kasper Pasternak Jørgensen. The company is owned by TIMPCO NB ApS, Alexander Meier Holding ApS and Pasternak Holding ApS. The company has 0 employees. In 2025, the company reported a gross profit of DKK -410,610 and a net result of DKK -665,070 compared with DKK -29,048 the year before. Equity amounted to DKK 325,631.